Furthermore, even when there was exposure only to synthetic peptide during vaccination, the T-cell repertoire naturally encompassed recognition of tumor-associated MUC1 [6], evidenced by reactivity to multiple, whole-cell tumor digests, and protection against in vivo tumor challenges, particularly when vaccination was continued post tumor challenge (Fig 6A). This evidence concerns the gene MUC1 and neoplasm.